The stock of Sanofi SA (ADR) (NYSE:SNY) is a huge mover today! About 578,887 shares traded hands. Sanofi SA (ADR) (NYSE:SNY) has declined 9.00% since March 11, 2016 and is downtrending. It has underperformed by 14.45% the S&P500.
The move comes after 8 months positive chart setup for the $96.53 billion company. It was reported on Oct, 14 by Barchart.com. We have $58.34 PT which if reached, will make NYSE:SNY worth $52.13 billion more.
Analysts await Sanofi SA (ADR) (NYSE:SNY) to report earnings on November, 3. They expect $0.87 EPS, down 2.25% or $0.02 from last year’s $0.89 per share. SNY’s profit will be $2.22B for 10.89 P/E if the $0.87 EPS becomes a reality. After $0.74 actual EPS reported by Sanofi SA (ADR) for the previous quarter, Wall Street now forecasts 17.57% EPS growth.
Sanofi SA (ADR) (NYSE:SNY) Ratings Coverage
Out of 7 analysts covering Sanofi-aventis Sa (NYSE:SNY), 3 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 43% are positive. Sanofi-aventis Sa has been the topic of 9 analyst reports since October 15, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating given on Thursday, May 12 by Barclays Capital. The firm earned “Overweight” rating on Thursday, October 15 by Morgan Stanley. On Friday, September 23 the stock rating was initiated by Piper Jaffray with “Neutral”. The stock of Sanofi SA (ADR) (NYSE:SNY) has “Underperform” rating given on Thursday, December 10 by BNP Paribas. The firm has “Mkt Perform” rating by Bernstein given on Monday, November 9. Berenberg upgraded the shares of SNY in a report on Thursday, September 8 to “Buy” rating. As per Tuesday, September 13, the company rating was upgraded by BNP Paribas. HSBC downgraded the stock to “Hold” rating in Tuesday, May 3 report.
According to Zacks Investment Research, “Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.”
SNY Company Profile
Sanofi, formerly Sanofi-Aventis, incorporated on May 11, 1994, is a healthcare firm engaged in the research, development, manufacture and marketing of therapeutic solutions. The Firm has three operating divisions: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from its subsidiary, Genzyme Corporation. The Company’s pharmaceuticals portfolio consists of products and a range of prescription medicines, generic medicines and consumer health products. The Pharmaceuticals segment also includes associates with activities related to pharmaceuticals. The Vaccines segment is dedicated to vaccines, including research, development, production and marketing. The Vaccines segment includes the Sanofi Pasteur MSD joint venture. The Animal Health segment includes the research, development, production and marketing activities of Merial, which offers a range of medicines and vaccines for a range of animal species. The Company’s Animal Health segment includes its subsidiaries, Merial, Inc. and Merial S.A.S. It also operates in the Other segment, which includes the effects of retained commitments in respect of divested activities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.